Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Pfizer Invites Public to View and Listen to Webcast of October 28 Conference Call with Analysts

Business Wire September 23, 2014

Kim Cattrall Encourages Women to Embrace Menopause with Style

Business Wire September 23, 2014

Bristol-Myers Squibb and Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for Patients and Caregivers

Business Wire September 22, 2014

Pfizer Foundation Provides $2 Million In Grants To Support 'Last-Mile' Vaccine Coverage In Africa

Business Wire September 19, 2014

ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

PR Newswire September 3, 2014

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire September 3, 2014

Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE)

Business Wire August 30, 2014

InnoPharma Announces FDA Approval of Decitabine for Injection, a Generic Version of DACOGEN®

PR Newswire August 29, 2014

Pfizer and Protalix BioTherapeutics Announce FDA Approval of Pediatric Indication for ELELYSO(TM) (taliglucerase alfa) for Injection, for Intravenous Use for the Treatment of Type 1 Gaucher Disease

Business Wire August 28, 2014

Pfizer's Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation

Business Wire August 28, 2014

UnitedHealth Group Inc. (UNH) Tops DJIA Gainers for August 27

Equities.com August 27, 2014

Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen

Business Wire August 26, 2014

Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

PR Newswire August 25, 2014

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

Canada NewsWire August 22, 2014

U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy

Business Wire August 21, 2014

Palbociclib Expanded Access Program Now Open To Eligible U.S. Patients With HR+, HER2- Advanced Breast Cancer

Business Wire August 21, 2014

Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014

Business Wire August 20, 2014

Premier Biotechnology & Anti-CTLA4

Accesswire August 18, 2014

Pfizer Announces Submission of Palbociclib New Drug Application to the FDA

Business Wire August 18, 2014

Pfizer Announces FDA Acceptance Of And Priority Review Designation For Biologics License Application For Investigational Meningococcal B Vaccine

Business Wire August 14, 2014